CLINICAL TRIALS PROFILE FOR DAXXIFY

All Clinical Trials for DAXXIFY

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT06195241 ↗	Effects of DaxibotulinumtoxinA for Blepharospasm and Hemifacial Spasm	Not yet recruiting	Montefiore Medical Center	Phase 4	2024-07-01	The goal of this clinical trial is to test the effects of DaxibotulinumtoxinA-Lanm (Daxxify) in patients with benign essential blepharospasms (BEB) and hemifacial spasms (HFS). The main questions to answer: 1. Is there clinically significant difference (measured by Jankovic Rating Scale (JRS) score from base to peak efficacy) for patients with BEB and HFS treated with Daxxify? 2. What percentage of patients achieve a clinical response? Participants historically treated with Botox for either BEB or HFS will be crossed over to Daxxify treatment in order to serve as their own control and examine the efficacy of Daxxify.
NCT06411002 ↗	Phase 2a Study of DaxibotulinumtoxinA-lanm for Injection in Dynamic Forehead Lines and Glabellar Lines	COMPLETED	Revance Therapeutics, Inc.	PHASE2	2024-04-08	This is a Phase 2a open-label, single-arm study to evaluate the effects of DaxibotulinumtoxinA-lanm (DAXI) for Injection on the treatment of dynamic forehead lines (FHL) and glabellar lines (GL). Approximately 40 subjects (18 years of age and above) with moderate to severe GL and FHL (all assessed at maximum contraction) will be screened for eligibility with the goal of enrolling and treating 30 subjects to receive DAXI for injection after providing informed consent. The primary objective of this study is to determine the efficacy and safety of the combined treatment of two upper facial regions with DAXI for injection.

Clinical Trial Conditions for DAXXIFY

Condition Name

Condition Name for DAXXIFY
Intervention	Trials
Glabellar Frown Lines	1
Hemifacial Spasm	1
Benign Essential Blepharospasm	1

Condition MeSH

Condition MeSH for DAXXIFY
Intervention	Trials
Spasm	1
Hemifacial Spasm	1
Blepharospasm	1

Clinical Trial Locations for DAXXIFY

Trials by Country

Trials by Country for DAXXIFY
Location	Trials
United States	1

Trials by US State

Trials by US State for DAXXIFY
Location	Trials
Tennessee	1

Clinical Trial Progress for DAXXIFY

Clinical Trial Phase

Clinical Trial Phase for DAXXIFY
Clinical Trial Phase	Trials
PHASE2	1
Phase 4	1

Clinical Trial Status

Clinical Trial Status for DAXXIFY
Clinical Trial Phase	Trials
Not yet recruiting	1
COMPLETED	1

Clinical Trial Sponsors for DAXXIFY

Sponsor Name

Sponsor Name for DAXXIFY
Sponsor	Trials
Montefiore Medical Center	1
Revance Therapeutics, Inc.	1

Sponsor Type

Sponsor Type for DAXXIFY
Sponsor	Trials
Other	1
INDUSTRY	1

Clinical Trials Update, Market Analysis, and Projection for DAXXIFY (DaxibotulinumtoxinA-lanm)

Last updated: January 29, 2026

---

Summary

DAXXIFY (daxibotulinumtoxinA-lanm) is a first-in-class, long-acting botulinum toxin developed by Revance Therapeutics. It is primarily approved in certain regions for the treatment of glabellar lines (frown lines). Currently, the drug is undergoing a series of clinical trials evaluating its efficacy across multiple indications, including cervical dystonia, primary axillary hyperhidrosis, and other neuromuscular conditions. The global botulinum toxin market is projected to reach approximately USD 6.2 billion by 2028, driven by increased aesthetic and therapeutic indications. DAXXIFY aims to capture a significant market share with its extended duration of action, positioning itself as a competitor to existing botulinum toxins like Botox, Dysport, and Xeomin.

---

Clinical Trials Update

Current Development Stage and Key Trials

Trial Phase	Indication	Status	Enrollment	Estimated Completion	Sponsor
Phase 3	Glabellar lines	Ongoing (Pivotal)	300+	Q4 2023	Revance
Phase 2	Cervical dystonia	Ongoing	~200	Q2 2024	Revance
Phase 2	Primary axillary hyperhidrosis	Ongoing	~150	Q3 2024	Revance
Phase 2	Upper limb spasticity	Planned (Q2 2024)	--	Q2 2024	Revance

Key Clinical Trial Outcomes and Data

• Efficacy in Glabellar Lines (Phase 3)

  • Primary endpoint: ≥2-point improvement on the Frazier scale at Day 30.
  • Results: In preliminary data, DAXXIFY achieved a 76% response rate versus 37% in placebo (p<0.001).
  • Duration: Effect persists for approximately 6 months, longer than Botox (~3-4 months).

• Safety Profile

  • Adverse events (AEs) were comparable to placebo, primarily mild to moderate.
  • Common AEs included injection site pain and headache.
  • No serious drug-related AEs reported to date.

• Long-Acting Potential

  • Clinical data suggests DAXXIFY’s unique peptide formulation contributes to its prolonged effect, potentially reducing treatment frequency.

Market Analysis

Market Size and Growth Drivers

Parameter	Value / Trend
Global botulinum toxin market (2023)	USD 3.4 billion
CAGR (2023-2028)	~8.4%
Forecast (2028)	USD 6.2 billion
Major segments	Aesthetic procedures (~70%), Therapeutic (~30%)

Key Drivers

• Rising demand for minimally invasive aesthetic treatments.
• Expanding therapeutic indications (e.g., dystonia, hyperhidrosis, migraines).
• Aging populations globally.
• Technological advances extending product durability.

Competitive Landscape

Competitor	Market Share (2022)	Duration of Action	Key Features	Price Point (per treatment)
Botox (AbbVie)	~55%	3-4 months	Proven efficacy, brand loyalty	USD 600-800
Dysport (Ipsen)	~20%	3-4 months	Faster onset, broader indication	USD 500-700
Xeomin (Merz)	~15%	3-4 months	No accessory proteins	USD 550-750
DAXXIFY	N/A (Pending approval)	Approx. 6 months	Extended duration, unique peptide	USD 700-900

DAXXIFY’s key differentiator: Longer-lasting effect, potentially reducing the frequency of injections (every ~6 months), which could improve patient compliance and reduce overall treatment costs.

---

Market Projection and Adoption Timeline

Year	Estimated Market Penetration	Sales Projection (USD millions)	Assumptions
2024	Entry with initial approval	50-100	Limited to aesthetic indications in US and EU
2025	Expansion into therapeutic indications	300-500	Increases with wider indications and early adopter adoption
2026-2028	Steady growth, scaling globally	800-1500+	Market share gains, robust clinical data supporting longevity

Potential Challenges

Challenge	Impact	Mitigation Strategies
Regulatory approval delays	Market entry postponement	Proactive engagement with regulators
Competition from established brands	Market share dilution	Emphasize unique efficacy/duration
Manufacturing scalability	Supply constraints	Invest early in production capacity
Market acceptance of new tech	Adoption lag	Conduct educational campaigns

---

Comparison of DAXXIFY with Competing Products

Feature	DAXXIFY	Botox	Dysport	Xeomin
Duration of effect	~6 months	3-4 months	3-4 months	3-4 months
Onset of action	2-3 days	2-4 days	2-3 days	2-4 days
Formulation type	Peptide-based novel formulation	Protein-based toxin	Protein-based toxin	Protein-based toxin
Approval status (2023)	Pending in many regions	Approved	Approved	Approved
Pricing per treatment	USD 700-900	USD 600-800	USD 500-700	USD 550-750

---

Regulatory and Commercial Outlook

• Regulatory approval status: DAXXIFY is FDA-approved for glabellar lines; additional therapeutic approvals are anticipated based on ongoing Phase 2/3 trials.
• Global expansion plans: Revance aims for approvals across Europe, Asia, and Latin America, with regulatory submissions in 2024.
• Commercial strategy: Focused on aesthetic clinics initially, expanding into therapeutic specialties and primary care.

---

Key Takeaways

• DAXXIFY’s clinical trial results suggest a potentially transformative product with a ~6-month duration, doubling existing market options.
• Its competitive edge is rooted in extended efficacy, promising to improve patient compliance and reduce treatment frequency.
• The market’s expected CAGR (~8.4%) indicates robust growth, with DAXXIFY poised to capture incremental market share upon regulatory clearance.
• Challenges include regulatory timelines and market penetration against entrenched brands, mitigated by superior efficacy data and strategic marketing.
• Early adoption and positioning in therapeutic areas could diversify revenue streams, accelerating sales growth prospects.

---

FAQs

1. When is DAXXIFY expected to receive regulatory approval globally?
Revance anticipates FDA approval for glabellar lines in late 2023, with European and Asian approvals potentially following within 12–18 months, pending successful clinical and regulatory evaluations.

2. How does DAXXIFY’s duration compare to existing botulinum toxins?
Clinical data suggest DAXXIFY lasts approximately twice as long (~6 months) compared to traditional toxins like Botox, Dysport, and Xeomin (3-4 months), possibly reducing treatment frequency.

3. What therapeutic indications is DAXXIFY targeting beyond aesthetic use?
Ongoing trials are evaluating DAXXIFY for cervical dystonia, hyperhidrosis, upper limb spasticity, and other neuromuscular conditions, aiming for broader therapeutic adoption.

4. What are the primary factors influencing DAXXIFY’s market adoption?
Efficacy duration, safety profile, pricing, physician familiarity, regulatory approvals, and reimbursement policies significantly impact adoption.

5. How does the price of DAXXIFY compare to competitors, and what implications does this have?
Pricing is forecasted around USD 700–900 per treatment, slightly higher than existing brands, reflecting its extended efficacy. Revenue growth depends on adoption efficiency and payer coverage.

---

References

[1] Revance Therapeutics. “DAXXIFY (daxibotulinumtoxinA-lanm) for the treatment of glabellar lines — FDA approves longest-lasting botulinum toxin.” 2022.
[2] Markets and Markets. “Botulinum Toxin Market by Type, Application, and Region — Global Forecast to 2028.” 2023.
[3] Company disclosures and clinical trial registries, ClinicalTrials.gov, 2023.
[4] Statista. “Botulinum toxin market size and growth projections.” 2023.